Yao L P, Li X X, Yu P Y, Xu J, Asico L D, Jose P A
Walter Reed Army Medical Centers and Georgetown University Medical Center, Washington, DC 20007, USA.
Hypertension. 1998 Dec;32(6):1049-53. doi: 10.1161/01.hyp.32.6.1049.
-Dopamine, via D1-like receptors, stimulates the activity of both protein kinase A (PKA) and protein kinase C (PKC), which results in inhibition of renal sodium transport. Since D1-like receptors differentially regulate sodium transport in normotensive and hypertensive rats, they may also differentially regulate PKC expression in these rat strains. Thus, 2 different D1-like agonists (fenoldopam or SKF 38393) were infused into the renal artery of anesthetized normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) (n=5 to 6/drug/strain). Ten or 60 minutes after starting the D1-like agonist infusion, both the infused kidney and the noninfused kidney that served as control were prepared for analysis. The D1-like agonists produced a greater diuresis and natriuresis and inhibited Na+,K+-ATPase activity in proximal tubule (PT) and medullary thick ascending limb (mTAL) to a greater extent in WKY (Delta20+/-1%) than in SHR (Delta7+/-1%, P<0.001). D1-like agonists had no effect on PKC-alpha or PKC-lambda expression in either membrane or cytosol but increased PKC-theta expression in PT in both WKY and SHR at 10 minutes but not at 60 minutes. However, membranous PKC-delta expression in PT and mTAL decreased in WKY but increased in SHR with either 10 or 60 minutes of D1-like agonist infusion. D1-like agonists also decreased membranous PKC-zeta expression in PT and mTAL in WKY but increased it in PT but not in mTAL in SHR. We conclude that there is differential regulation of PKC isoform expression by D1-like agonists that inhibits membranous PKC-delta and PKC-zeta in WKY but stimulates them in SHR; this effect in SHR is similar to the stimulatory effect of norepinephrine and angiotensin II and may be a mechanism for their differential effects on sodium transport.
多巴胺通过 D1 样受体刺激蛋白激酶 A(PKA)和蛋白激酶 C(PKC)的活性,这会导致肾钠转运受到抑制。由于 D1 样受体在正常血压大鼠和高血压大鼠中对钠转运的调节存在差异,它们在这些大鼠品系中对 PKC 表达的调节可能也存在差异。因此,将两种不同的 D1 样激动剂(非诺多泮或 SKF 38393)注入麻醉的正常血压 Wistar-Kyoto 大鼠(WKY)和自发性高血压大鼠(SHR)(每种药物/品系 n = 5 至 6 只)的肾动脉。在开始注入 D1 样激动剂 10 或 60 分钟后,将注入药物的肾脏以及作为对照的未注入药物的肾脏用于分析。D1 样激动剂在 WKY(变化 20±1%)中比在 SHR(变化 7±1%,P<0.001)中产生更大的利尿和利钠作用,并在更大程度上抑制近端小管(PT)和髓质厚升支(mTAL)中的 Na +,K + -ATP 酶活性。D1 样激动剂对膜或细胞质中的 PKC-α 或 PKC-λ 表达没有影响,但在 10 分钟而非 60 分钟时,在 WKY 和 SHR 的 PT 中均增加了 PKC-θ 的表达。然而,在注入 D1 样激动剂 10 或 60 分钟后,WKY 的 PT 和 mTAL 中的膜 PKC-δ 表达降低,而 SHR 中的则增加。D1 样激动剂还降低了 WKY 的 PT 和 mTAL 中的膜 PKC-ζ 表达,但在 SHR 的 PT 中增加,而在 mTAL 中未增加。我们得出结论,D1 样激动剂对 PKC 同工型表达存在差异调节,在 WKY 中抑制膜 PKC-δ 和 PKC-ζ,但在 SHR 中刺激它们;这种在 SHR 中的作用类似于去甲肾上腺素和血管紧张素 II 的刺激作用,可能是它们对钠转运产生差异作用的一种机制。